Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 3995
Single User License Price INR 287320
Corporate User License Price USD 11985
Corporate User License Price INR 861961
Site License Price USD 7990
Site License Price INR 574641
Request a Quote

Report Title

EpiCast Report: Fibromyalgia-Epidemiology Forecast to 2023

Quote Request for License Type
License Type Price  
Single User License USD 3995
Site License USD 7990
Enterprise Wide License USD 11985
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

EpiCast Report: Fibromyalgia-Epidemiology Forecast to 2023


Quote Request for License Type
License Type Price  
Single User License USD 3995
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

EpiCast Report: Fibromyalgia-Epidemiology Forecast to 2023

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

EpiCast Report: Fibromyalgia-Epidemiology Forecast to 2023



Executive Summary

EpiCast Report: Fibromyalgia-Epidemiology Forecast to 2023

Fibromyalgia, also known as fibromyalgia syndrome and fibrositis, is a common form of nonarticular rheumatism that is associated with chronic, widespread musculoskeletal pain, generalized tender joints, fatigue, and a long list of wide-ranging symptoms, such as fatigue, sleep disturbances, irritable bowel syndrome (IBS), headaches, and depression. Fibromyalgia is a complex illness to diagnose and treat, as it is idiopathic, and its symptoms may be part of or overlap with other diseases.

For this analysis, GlobalData epidemiologists defined fibromyalgia using the International Classification of Diseases, Ninth Revision (ICD-9) code for fibromyalgia (729.1) and the International Classification of Diseases, Tenth Revision (ICD-10) code for fibromyalgia (M79.7). GlobalData epidemiologists used country-specific studies that provided the total prevalence of fibromyalgia using the 2010 American College of Rheumatology (ACR) classification criteria for this epidemiological forecast.

In 2013, there were 23,663,533 total prevalent cases of fibromyalgia in the 7MM. GlobalData epidemiologists forecast that the total prevalent cases in the 7MM will increase to 24,881,838 by 2023, at an Annual Growth Rate (AGR) of 0.51%. All markets, except for Germany and Japan, will see a small increase in the number of cases at varying AGRs. Since GlobalData epidemiologists held the prevalence constant throughout the forecast period, the differences observed in the total prevalent cases of fibromyalgia in the 7MM are driven by changes in the underlying population dynamics of each market.

In the 7MM, fibromyalgia epidemiological studies have shown that women have a higher total prevalence of fibromyalgia compared with men. When the 1990 ACR criteria were used to define fibromyalgia, a majority of patients with fibromyalgia were women due to the greater number of female body tender points. However, the 2010 ACR criteria are entirely symptom-based, do not require tender point counts, and provide a more accurate sex distribution of total prevalent cases of fibromyalgia (Wolfe et al., 2011). Additional studies are needed to clarify the etiology of the association between sex and fibromyalgia.

Scope

The Fibromyalgia EpiCast Report provides an overview of the risk factors, global, and historical trends of fibromyalgia in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiology forecast of fibromyalgia total prevalent cases segmented by age (in five-year increments for all ages), sex, and pain severity (mild, moderate, and severe) in these seven markets.

The fibromyalgia epidemiology report is written and developed by Masters- and PhD-level epidemiologists.

The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons To Buy

Develop business strategies by understanding the trends shaping and driving the global fibromyalgia market.

Quantify patient populations in the global fibromyalgia market to improve product design, pricing, and launch plans.

Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for fibromyalgia therapeutics in each of the markets covered.

Identify the percentage of fibromyalgia total prevalent cases by severity.

1 Table of Contents

1 Table of Contents 3

1.1 List of Tables 5

1.2 List of Figures 5

2 Introduction 6

2.1 Catalyst 6

2.2 Related Reports 7

2.3 Upcoming Related Reports 7

3 Epidemiology 8

3.1 Disease Background 8

3.2 Risk Factors and Comorbidities 8

3.3 Global Trends 10

3.3.1 US 12

3.3.2 5EU 12

3.3.3 Japan 12

3.4 Forecast Methodology 13

3.4.1 Sources Used 13

3.4.2 Sources Not Used 17

3.4.3 Forecast Assumptions and Methods-Total Prevalent Cases of Fibromyalgia 18

3.4.4 Forecast Assumptions and Methods-Fibromyalgia Pain Severity 20

3.5 Epidemiological Forecast for Fibromyalgia (2013-2023) 21

3.5.1 Total Prevalent Cases of Fibromyalgia 21

3.5.2 Age-Specific Total Prevalent Cases of Fibromyalgia 23

3.5.3 Sex-Specific Total Prevalent Cases of Fibromyalgia 25

3.5.4 Age-Standardized Total Prevalence of Fibromyalgia 27

3.5.5 Total Prevalent Cases of Fibromyalgia by Pain Severity 28

3.6 Discussion 30

3.6.1 Epidemiological Forecast Insight 30

3.6.2 Limitations of the Analysis 32

3.6.3 Strengths of the Analysis 33

4 Appendix 34

4.1 Bibliography 34

4.2 About the Authors 37

4.2.1 Epidemiologists 37

4.2.2 Reviewers 37

4.2.3 Global Director of Therapy Analysis and Epidemiology 38

4.2.4 Global Head of Healthcare 39

4.3 About GlobalData 40

4.4 About EpiCast 40

4.5 Disclaimer 41

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

1.2 List of Figures

Figure 1: 7MM, Total Prevalent Cases of Fibromyalgia Ages ?10 Years, Both Sexes, N, 2013-2023 23

Figure 2: 7MM, Age-Specific Total Prevalent Cases of Fibromyalgia, Both Sexes, N, 2013 25

Figure 3: 7MM, Sex-Specific Total Prevalent Cases of Fibromyalgia, Ages ?10 Years, N, 2013 27

Figure 4: 7MM, Age-Standardized Total Prevalence of Fibromyalgia (%), Ages ?10 Years, by Sex, 2013 28

Figure 5: 7MM Total Prevalent Cases of Fibromyalgia (N), by Pain Severity, Both Sexes, Ages ?10 Years, 2013 30

1.1 List of Tables

Table 1: Risk Factors and Comorbidities for Fibromyalgia 9

Table 2: Comparison of the ACR Criteria for Fibromyalgia Classification 11

Table 3: 7MM, Sources of Total Prevalence Data Used to Forecast the Total Prevalent Cases of Fibromyalgia 13

Table 4: 7MM, Sources of Fibromyalgia Pain Severity Data Used to Forecast the Total Prevalent Cases of Fibromyalgia Segmented by Pain Severity 14

Table 5: 7MM, Total Prevalent Cases of Fibromyalgia, Ages ?10 Years, Both Sexes, N, Selected Years 2013-2023 22

Table 6: 7MM, Age-Specific Total Prevalent Cases of Fibromyalgia, Both Sexes, N (Row %), 2013 24

Table 7: 7MM, Sex-Specific Total Prevalent Cases of Fibromyalgia, Ages ?10 Years, N (Row %), 2013 26

Table 8: 7MM Total Prevalent Cases of Fibromyalgia, N (%), by Pain Severity, Both Sexes, Ages ?10 Years, 2013 29

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand